01Harmony Biosciences reported Q3 EPS of $0.81, missing consensus estimate of $1.37 by $0.56 per share, a 41% shortfall.
02Revenue came in at $268.9M, slightly below the $271.8M estimate, representing a modest revenue miss.
03The company's earnings have been volatile, with Q2 2026 beating estimates by 21.9% but Q1 and Q4 2025 missing by approximately 39-42%.
04HRMY stock trades at $33.42 with a $2.3B market capitalization following the earnings release.
Earnings Results
Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings results on November 04, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $0.81, missing the consensus estimate of $1.37 by $0.56 per share. Revenue came in at $268.9M, missing the estimate of $271.8M.
Company Overview
Harmony Biosciences's stock moved following the earnings release. The stock currently trades at $33.42 with a market capitalization of $2.3B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 41% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Harmony Biosciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.